The DOI matches its Crossref record.
Prognosis and Breast Cancer: Recognition of Lethal and Favorable Prognostic Types
Abstract
Assignment of breast cancer patients to specific prognostic groups has been a relatively empty exercise until the recent acceptance of the effectiveness of systemic chemotherapy. The previous question of who should be so treated has changed in North America to a question of who should not be so treated. The availability of intensive chemotherapy for the worst prognostic groups as well as efficacious, low-toxicity adjuvant chemotherapy has made prognostication mandatory. The current major question is which women with breast cancer will not benefit from chemotherapy. We are actually much better at prognostication than many studies and the current broad search for new prognostic markers would indicate. The assignment of excellent prognosis categories by defined special histologic types or grade of breast cancer as well as other measures recognize women with survival approaching or equaling the general population. Likewise, extremely poor prognosis may be recognized in 20% to 40% of women with breast cancer by the presence of extensive mitoses or high proliferation index (by any modality) and poor differentiation (highest grade). Combined tumor size and nodal status data with high-grade indicates that women with these indicators will die within 2 to 3 years with as high as 80% certainty. The surgical pathologist still determines if cancer is present and must also determine if the tumor is in situ or invasive, its type or grade if invasive, and the extent of in situ component. Considering the diminution in overall size of cancers detected by modern techniques, it is clear that validation of newer prognostic variables will be more useful and will allow more separate determinations if adapted to tissue sections rather than tissue homogenates. The many measures of these carcinomas, such as size and nodal status, make multiparametric assessment of putative prognostic markers mandatory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Breast cancer metastasis: markers and models
Weigelt, B., Peterse, J. L., & van't Veer, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1670 · Cited by 2,232
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Bos, R., van der Groep, P., Greijer, A. E., Shvarts, A., Meijer, S., Pinedo, H. M., Semenza, G. L., van Diest, P. J., & van der Wall, E. (2003) · Cancer · doi:10.1002/cncr.11246 · Cited by 500
On behalf of the TRANSBIG consortium, Mook, S., Schmidt, M. K., Viale, G., Pruneri, G., Eekhout, I., Floore, A., Glas, A. M., Bogaerts, J., Cardoso, F., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0130-2 · Cited by 299
Khan, M. W., Saadalla, A., Ewida, A. H., Al-Katranji, K., Al-Saoudi, G., Giaccone, Z. T., Gounari, F., Zhang, M., Frank, D. A., & Khazaie, K. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2057-0 · Cited by 103
Metadata
- Authors
- Page, D. L.
- Venue
- The American Journal of Surgical Pathology
- Published
- 1991-04
- Volume
- 15
- Issue
- 4
- Pages
- 334-349
- ISSN
- 0147-5185 (ISSN-L)
- OpenAlex
- W2328364787
- Cited by
- 189
- References
- 0
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognosis and Breast Cancer: Recognition of Lethal and Favorable Prognostic Types. https://app.cochat.ai/papers/10.1097/00000478-199104000-00002
- The paper
- Page, D. L. (1991). Prognosis and Breast Cancer: Recognition of Lethal and Favorable Prognostic Types. The American Journal of Surgical Pathology. https://doi.org/10.1097/00000478-199104000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.